Endocrine Abstracts

Patients on long term prednisolone therapy have suppression of their hypothalamo-pituitary-adrenal (HPA) axis. The short synacthen test (SST) is routinely employed to assess the viability of the HPA axis. However, as this test examines only adrenal function it may fail to identify those patients with secondary adrenal insufficiency. The overnight metyrapone test (OMT) may be a better test as it examines the whole HPA axis.We have compared the responses t...

A 37 year-old gentleman presented following an episode of dizziness while at work operating a fork-lift truck. There was no collapse or associated symptoms. He had been diagnosed with autoimmune hypothyroidism two months previously; commenced levothyroxine, currently at a dose of 75 micrograms daily; and lost ten kilograms in weight. On examination there were no signs of hypoadrenalism aside from a significant postural drop in blood pressure (lying 1...

A 37 year-old gentleman presented following an episode of dizziness while at work operating a fork-lift truck. There was no collapse or associated symptoms. He had been diagnosed with autoimmune hypothyroidism two months previously; commenced levothyroxine, currently at a dose of 75 micrograms daily; and lost ten kilograms in weight. On examination there were no signs of hypoadrenalism aside from a significant postural drop in blood pressure (lying 1...

Background: Pituitary abscess is rare but a serious intrasellar infection. It should be considered in the differential diagnosis of the sellar masses due to its high morbidity and mortality rates. Despite recent advances in radiological investigations, it remains a challenge to make a definitive diagnosis preoperatively [1]. We present a case of pituitary abscess who presented with pan hypopituitarism and central diabetes insipidus.Case presen...

Paltusotine is a once-daily, oral selective nonpeptide somatostatin receptor type 2 (SST2) agonist, which is in clinical development for the treatment of acromegaly. Maintenance of insulin-like growth factor 1 (IGF-1) control and toleration was demonstrated in phase 2 studies evaluating paltusotine in biochemically controlled (IGF-1 ≤1xULN) [ACROBAT Evolve (NCT03792555)] and uncontrolled (1> IGF-1 ≤2.5xULN) [ACROBAT Edge (NCT03789656)] patients with acromegaly ...

Paltusotine is a once-daily, oral, nonpeptide somatostatin receptor type 2 (SST2) specific agonist, in development for the treatment of acromegaly and neuroendocrine tumors. We report interim results from ACROBAT Advance (NCT04261712), an ongoing, multicenter, open-label, long-term extension study of paltusotine in subjects with acromegaly who previously completed either Phase 2 study ACROBAT Edge (NCT03789656) or Evolve (NCT03792555). ACROBAT Edge enrolled 47 subjects with el...

Germline mutations in BRAF and other components of the RAS/MAPK pathway are found in RASopathies, whose features include short stature and pubertal delay. The underlying mechanism of endocrinopathies in RASopathies has not been fully elucidated. We report four BRAF mutations (two of which are novel) in four children with congenital hypopituitarism and RASopathy features. To demonstrate the functional role of the variants we performed phosphoproteomic analyses...